Our main findings indicate that (i) fluid tau biomarker abnormalities might reflect the underlying extent of tau neurofibrillary pathology, (ii) CSF and plasma-based staging may provide valuable information regarding the biomarker phenotype of AD patients, and (iii) biofluid stages are not interchangeable between CSF and plasma in all individuals. The gene discussed is MAPT; the disease is Alzheimer disease.